Drugmaker Inks $2.5M Deal In Failed Weight Loss Drug Suit
Drugmaker Skye Bioscience Inc. has reached a $2.5 million settlement with investors that would end a proposed securities class action alleging the company overhyped a weight-loss drug, causing its stock price...To view the full article, register now.
Already a subscriber? Click here to view full article